Atlas Trials

Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS

Clinical trial NCT03802799 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03802799
Sponsor
Zynerba Pharmaceuticals, Inc.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Fragile X Syndrome
Start date
2018-11-09
Primary completion
2026-06-30
Enrollment
476

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.